

Bortezomib with lenalidomide and dexamethasone versus
alone in patients with newly diagnosed myeloma without
stem-cell transplant (SWOG S0777): a randomised, open

Lancet, The

389, 519-527

DOI: [10.1016/s0140-6736\(16\)31594-x](https://doi.org/10.1016/s0140-6736(16)31594-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. <i>Blood</i> , 2016, 128, 2757-2764.	0.6	63
2	Treatment of newly diagnosed myeloma: Bortezomib-based triplet. <i>Seminars in Oncology</i> , 2016, 43, 700-702.	0.8	9
3	Proteasome inhibitors in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 417-433.	12.5	675
4	Fresh perspectives on treatment and moments of clarity. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 73-74.	12.5	9
5	Landmark survival achieved in MM. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 139-139.	12.5	0
6	Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. <i>Journal of Internal Medicine</i> , 2017, 281, 365-382.	2.7	128
7	How I manage the toxicities of myeloma drugs. <i>Blood</i> , 2017, 129, 2359-2367.	0.6	44
8	Study design for vulnerable older adults with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2017, 8, 162-164.	0.5	0
9	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv52-iv61.	0.6	619
10	Proteasome inhibitor-induced gastrointestinal toxicity. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 133-137.	0.5	16
11	The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population. <i>JAMA Oncology</i> , 2017, 3, 1345.	3.4	24
12	New Treatment Options for the Management of Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 709-712.	2.3	5
13	Where are we now with the treatment of multiple myeloma?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 461-462.	12.5	11
14	Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication. <i>Bone Marrow Transplantation</i> , 2017, 52, 832-838.	1.3	24
15	Pharmacologic Ascorbate in Myeloma Treatment: Doses Matter. <i>EBioMedicine</i> , 2017, 18, 9-10.	2.7	6
16	Transplantation for Myeloma – Now or Later?. <i>New England Journal of Medicine</i> , 2017, 376, 1378-1379.	13.9	5
17	Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1193-1202.	2.0	14
18	Multiple myeloma: new treatments gain momentum. <i>Lancet, The</i> , 2017, 389, 480-482.	6.3	2

#	ARTICLE	IF	CITATIONS
19	Multiple Myeloma: State of the Art. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S134-S136.	0.2	0
20	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood, 2017, 130, 2610-2618.	0.6	90
21	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Targeted Oncology, 2017, 12, 643-654.	1.7	19
22	Impact of lenalidomide-based induction therapy on the mobilization of CD34 ⁺ cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study. Transfusion, 2017, 57, 2366-2372.	0.8	7
23	Multiple myeloma. Nature Reviews Disease Primers, 2017, 3, 17046.	18.1	812
24	Very-Low-Dose Lenalidomide for Elderly and/or Frail Multiple Myeloma Patients: Lower Might Be Better. Acta Haematologica, 2017, 138, 52-54.	0.7	1
25	Measuring higher-order drug interactions: A review of recent approaches. Current Opinion in Systems Biology, 2017, 4, 16-23.	1.3	29
26	How I treat myeloma with new agents. Blood, 2017, 130, 1507-1513.	0.6	65
27	The proteasome and proteasome inhibitors in multiple myeloma. Cancer and Metastasis Reviews, 2017, 36, 561-584.	2.7	229
28	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opinion on Pharmacotherapy, 2017, 18, 1975-1985.	0.9	10
29	Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia, 2017, 31, 2695-2701.	3.3	32
30	Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 575-583.e2.	0.2	71
31	How I treat first relapse of myeloma. Blood, 2017, 130, 963-973.	0.6	58
32	Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma. Seminars in Oncology Nursing, 2017, 33, 279-291.	0.7	9
33	Safety of ixazomib for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 2017, 16, 973-980.	1.0	16
34	Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma. Seminars in Oncology, 2017, 44, 381-384.	0.8	4
35	Adjonction du bortézomib à l'association lenalidomide-dexaméthasone dans le myélome multiple sans indication prémière à autogreffe de cellules souches hématopoïétiques. Hematologie, 2017, 23, 103-104.	0.0	0
36	Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 2399-2408.	2.0	32

#	ARTICLE	IF	CITATIONS
38	Cure of Insulin-Dependent Diabetes Mellitus by an Autologous Hematopoietic Stem Cell Transplantation Performed to Control Multiple Myeloma in a Patient with Chronic Renal Failure on Regular Hemodialysis. <i>Journal of Stem Cell Biology and Transplantation</i> , 2017, 1, .	0.3	5
39	Management of multiple myeloma in the newly diagnosed patient. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 498-507.	0.9	64
40	Myeloma in Elderly Patients: When Less Is More and More Is More. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 575-585.	1.8	16
41	Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 19.	0.4	22
42	Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. <i>Annals of Hematology</i> , 2018, 97, 925-944.	0.8	27
43	Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. <i>European Journal of Haematology</i> , 2018, 101, 237-244.	1.1	107
44	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	1.2	8
45	The multiple myelomas "current concepts in cytogenetic classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 409-421.	12.5	203
46	A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 1083-1093.	1.1	11
47	Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. <i>Cancer Science</i> , 2018, 109, 1552-1561.	1.7	10
48	How We Manage Patients with Plasmacytomas. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 227-235.	1.2	10
49	Short overview on the current standard of treatment in newly diagnosed multiple myeloma. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 59-64.	0.3	8
50	The start of a new wave: Developments in proteasome inhibition in multiple myeloma. <i>European Journal of Haematology</i> , 2018, 101, 220-236.	1.1	15
52	Treatment of Elderly Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018, , 61-71.	0.2	1
53	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , 2018, 59, 2305-2317.	0.6	18
55	Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. <i>Leukemia</i> , 2018, 32, 986-995.	3.3	60
56	Therapy sequencing strategies in multiple myeloma: who, what and why?. <i>Future Oncology</i> , 2018, 14, 95-99.	1.1	4
57	Upfront treatment of elderly myeloma patients: an overview and update. <i>Expert Review of Hematology</i> , 2018, 11, 99-108.	1.0	3

#	ARTICLE	IF	CITATIONS
58	Triplet vs. doublet drug regimens for managing multiple myeloma. Expert Opinion on Pharmacotherapy, 2018, 19, 137-149.	0.9	21
59	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. JAMA Oncology, 2018, 4, 343.	3.4	130
60	The evolution of stem-cell transplantation in multiple myeloma. Therapeutic Advances in Hematology, 2018, 9, 123-133.	1.1	31
61	MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. Seminars in Hematology, 2018, 55, 44-50.	1.8	31
62	Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia, 2018, 32, 1267-1276.	3.3	18
63	Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. Drugs and Aging, 2018, 35, 289-302.	1.3	2
64	Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. , 2018, , 551-571.		0
65	Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA) Tj ETQq1 1 0.3843142gBT /Over	0.3843142	0
67	Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 2018, 182, 739-741.	1.2	1
68	Managing multiple myeloma in elderly patients. Leukemia and Lymphoma, 2018, 59, 1300-1311.	0.6	18
69	New agents in the Treatment of Myeloma Bone Disease. Calcified Tissue International, 2018, 102, 196-209.	1.5	37
70	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood, 2018, 131, 301-310.	0.6	216
72	Global Approaches in Myeloma: Critical Trials That May Change Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 656-661.	1.8	4
73	Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. Journal of Clinical Oncology, 2018, 36, 2012-2016.	0.8	2
74	Practical Considerations for Antibodies in Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 667-674.	1.8	6
75	Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. Journal of Clinical Oncology, 2018, 36, 2879-2886.	0.8	12
76	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 234-241.	1.4	24
77	Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Agents and Targeted Therapies. Journal of Stem Cell Biology and Transplantation, 2018, 02, .	0.3	0

#	ARTICLE	IF	CITATIONS
78	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.	2.8	16
79	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone. <i>JAMA Oncology</i> , 2018, 4, 1781.	3.4	33
80	The power of proteasome inhibition in multiple myeloma. <i>Expert Review of Proteomics</i> , 2018, 15, 1033-1052.	1.3	33
81	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1949-1968.	0.9	42
82	Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. <i>British Journal of Haematology</i> , 2018, 184, 735-743.	1.2	2
83	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.	2.8	29
84	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 306-311.	2.0	18
85	Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. <i>Lancet Haematology</i> , 2018, 5, e628-e640.	2.2	15
86	Special problems in the management of elderly patients with multiple myeloma. <i>European Journal of Internal Medicine</i> , 2018, 58, 64-69.	1.0	1
87	The forgotten class of drugs for multiple myeloma: HDAC inhibitors. <i>Lancet Haematology</i> , 2018, 5, e604-e605.	2.2	6
88	Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma. <i>PLoS ONE</i> , 2018, 13, e0196780.	1.1	24
89	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2018, 132, 2555-2563.	0.6	54
90	Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1019-1026.	0.5	14
91	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 9-16.	2.0	13
92	Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2018, 132, 2546-2554.	0.6	110
93	Triplet therapies "the new standard of care for multiple myeloma: how to manage common toxicities. <i>Expert Review of Hematology</i> , 2018, 11, 957-973.	1.0	7
94	RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. <i>Blood</i> , 2018, 132, 2154-2165.	0.6	14
95	Abducens Nerve Palsy as Initial Presentation of Multiple Myeloma and Intracranial Plasmacytoma. <i>Journal of Clinical Medicine</i> , 2018, 7, 253.	1.0	7

#	ARTICLE	IF	CITATIONS
96	Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist. Hematology American Society of Hematology Education Program, 2018, 2018, 83-87.	0.9	7
97	Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. Hematology American Society of Hematology Education Program, 2018, 2018, 88-96.	0.9	18
98	Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients. Hematology American Society of Hematology Education Program, 2018, 2018, 103-109.	0.9	1
99	Treatment approach for young, fit, newly diagnosed multiple myeloma patients. Hematology American Society of Hematology Education Program, 2018, 2018, 97-102.	0.9	6
100	Potent antitumor effect of combination therapy with suboptimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma. Oncology Letters, 2018, 15, 9450-9456.	0.8	10
101	Determining treatment intensity in elderly patients with multiple myeloma. Expert Review of Anticancer Therapy, 2018, 18, 917-930.	1.1	10
102	A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica, 2018, 103, 1518-1526.	1.7	18
103	How I treat the young patient with multiple myeloma. Blood, 2018, 132, 1114-1124.	0.6	38
104	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 2018, 182, 231-244.	1.2	30
105	Maintenance and continuous therapy for multiple myeloma. Expert Review of Anticancer Therapy, 2018, 18, 751-764.	1.1	10
106	The role of carfilzomib in treatment of newly diagnosed multiple myeloma. Future Oncology, 2018, 14, 3123-3134.	1.1	3
107	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	2.8	18
108	Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma. Annals of Hematology, 2018, 97, 2447-2454.	0.8	4
109	Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. Clinical Therapeutics, 2018, 40, 1193-1202.e1.	1.1	10
110	Second primary malignancy after multiple myeloma—population trends and cause-specific mortality. British Journal of Haematology, 2018, 182, 513-520.	1.2	25
111	Update on the role of lenalidomide in patients with multiple myeloma. Therapeutic Advances in Hematology, 2018, 9, 175-190.	1.1	42
112	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. International Journal of Molecular Sciences, 2018, 19, 2087.	1.8	14
113	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. British Journal of Haematology, 2018, 182, 222-230.	1.2	118

#	ARTICLE	IF	CITATIONS
114	Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 182, 165-167.	1.2	0
115	The safety of bortezomib for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 953-962.	1.0	64
116	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
117	Proteasome inhibitors for multiple myeloma. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 785-793.	0.6	37
118	Multiple myeloma: 2018 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2018, 93, 1091-1110.	2.0	166
119	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
120	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.2	9
121	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	3.3	83
122	Targeting Protein-Protein Interactions in the Ubiquitin-Proteasome Pathway. <i>Advances in Protein Chemistry and Structural Biology</i> , 2018, 110, 123-165.	1.0	12
123	Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. <i>Clinical Pharmacokinetics</i> , 2019, 58, 157-168.	1.6	92
124	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
125	Development of a prognostic model for overall survival in multiple myeloma using the Connect MM Patient Registry. <i>British Journal of Haematology</i> , 2019, 187, 602-614.	1.2	11
126	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naïve multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e448-e458.	2.2	168
127	Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 645-655.	0.2	15
128	Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 979-992.	0.6	3
129	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2019, 94, 1176-1184.	2.0	112
130	Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies. , 2019, , .		4
131	Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone. <i>European Journal of Haematology</i> , 2019, 103, 385-392.	1.1	1

#	ARTICLE	IF	CITATIONS
132	Are triplet therapies really living up to their hype as the "standard of care" for multiple myeloma and what else is needed?. Expert Review of Hematology, 2019, 12, 699-701.	1.0	1
133	Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data. British Journal of Haematology, 2019, 187, 470-477.	1.2	12
134	Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. Expert Review of Hematology, 2019, 12, 665-684.	1.0	13
135	Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. Journal of Hematology and Oncology, 2019, 12, 65.	6.9	7
136	Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma. Cancer Medicine, 2019, 8, 6945-6954.	1.3	5
137	RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group. Annals of Hematology, 2019, 98, 2781-2792.	0.8	12
138	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 84-94.	2.8	35
140	Bortezomib and other proteasome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S52-S62.	1.4	30
141	Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer Journal, 2019, 9, 70.	2.8	17
142	Life Beyond RVD: The Future of Induction Therapy for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S22-S23.	0.2	0
143	Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood, 2019, 134, 1337-1345.	0.6	148
144	Management of Multiple Myeloma in Developing Countries. , 2019, , .		2
145	A Network Analysis of Multiple Myeloma Related Gene Signatures. Cancers, 2019, 11, 1452.	1.7	23
146	Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma. Molecular Omics, 2019, 15, 7-20.	1.4	9
147	Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?. Current Hematologic Malignancy Reports, 2019, 14, 31-38.	1.2	15
148	Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage Therapies. Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Over	1.0	6
149	Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. Cancer Journal (Sudbury, Mass), 2019, 25, 19-31.	1.0	7
150	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia, 2019, 33, 1736-1746.	3.3	45

#	ARTICLE	IF	CITATIONS
151	Risk adapted post-transplant maintenance in multiple myeloma. <i>Expert Review of Hematology</i> , 2019, 12, 107-118.	1.0	7
152	The therapeutic role of natural killer cells in multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e49.	0.6	2
153	<p>Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1707-1716.	2.0	12
154	Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 459-473.	1.5	10
155	Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. <i>European Journal of Haematology</i> , 2019, 103, 247-254.	1.1	11
156	Management of Newly Diagnosed Elderly Multiple Myeloma Patients. <i>Current Oncology Reports</i> , 2019, 21, 64.	1.8	16
157	Initial Therapy in Older Patients with Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2172-2173.	13.9	4
158	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	13.9	684
159	Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 570-578.e1.	0.2	20
160	Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. <i>BMC Cancer</i> , 2019, 19, 504.	1.1	25
161	Registering a CD38 antibody upfront for multiple myeloma. <i>Lancet, The</i> , 2019, 394, 3-4.	6.3	0
162	Multiple myeloma: Every year a new standard?. <i>Hematological Oncology</i> , 2019, 37, 62-65.	0.8	155
163	Immunomodulatory drugs in the treatment of multiple myeloma. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 695-702.	0.6	17
164	Quality of life in multiple myeloma: considerations and recommendations. <i>Expert Review of Hematology</i> , 2019, 12, 419-424.	1.0	32
165	Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 187-196.	1.2	8
166	Induction Therapy for Newly Diagnosed Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e176-e186.	1.8	28
167	Approach to the Older Adult With Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 500-518.	1.8	36
168	Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e478-e488.	0.2	10

#	ARTICLE	IF	CITATIONS
169	Is there still a role for stem cell transplantation in multiple myeloma?. Cancer, 2019, 125, 2534-2543.	2.0	23
170	Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs in R and D, 2019, 19, 73-92.	1.1	98
171	Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer Journal, 2019, 9, 36.	2.8	11
172	Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer Journal, 2019, 9, 38.	2.8	52
173	Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best Practice and Research in Clinical Haematology, 2019, 32, 54-64.	0.7	12
174	Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 207-228.		1
175	Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma. Current Oncology Reports, 2019, 21, 35.	1.8	5
176	Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. Expert Opinion on Investigational Drugs, 2019, 28, 421-433.	1.9	8
177	MAIA under the microscope " bringing trial design into focus. Nature Reviews Clinical Oncology, 2019, 16, 339-340.	12.5	10
178	Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2019, 9, 44.	2.8	175
179	Multiples Myelom - es ist vieles im Wandel. Karger Kompass Onkologie, 2019, 6, 6-8.	0.0	0
180	Multiple Myeloma: Current Advances and Future Directions. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 255-263.	0.2	27
181	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). International Journal of Hematology, 2019, 109, 509-538.	0.7	27
182	Chemotherapy and Beyond. Infectious Disease Clinics of North America, 2019, 33, 289-309.	1.9	34
183	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1228-1263.	0.8	190
184	Substratification of patients with newly diagnosed standard-risk multiple myeloma. British Journal of Haematology, 2019, 185, 254-260.	1.2	12
185	New proteasome inhibitors in the treatment of multiple myeloma. Hematology, Transfusion and Cell Therapy, 2019, 41, 76-83.	0.1	25
186	Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. American Journal of Hematology, 2019, 94, 539-545.	2.0	4

#	ARTICLE	IF	CITATIONS
187	Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 70-82.	1.2	16
188	Management of cardiovascular risk in patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 26.	2.8	71
189	Registration studies “when should patients be deemed ineligible for aggressive therapy?”. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 333-334.	12.5	2
190	The pharmacologic management of multiple myeloma in older adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 887-902.	0.9	11
191	Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France. <i>Advances in Hematology</i> , 2019, 2019, 1-12.	0.6	9
192	Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. , 2019, 7, 35.		20
193	Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass.)</i> , 2019, 25, 2-10.	1.0	10
194	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	2.5	37
195	Supervised and home-based physical exercise in patients newly diagnosed with multiple myeloma—a randomized controlled feasibility study. <i>Pilot and Feasibility Studies</i> , 2019, 5, 130.	0.5	21
196	Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. <i>Cancers</i> , 2019, 11, 2015.	1.7	26
197	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , 2019, 9, 94.	2.8	104
198	Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 2020, .	1.5	21
199	Frontline treatment of multiple myeloma. <i>HemaSphere</i> , 2019, 3, 127-130.	1.2	4
200	Stem-cell transplantation in multiple myeloma: how far have we come?. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071988811.	1.1	18
201	Daratumumab in untreated newly diagnosed multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071989487.	1.1	31
203	Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 9-22.	0.2	21
204	Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. <i>Blood</i> , 2019, 133, 652-659.	0.6	41
206	Current role of high dose chemotherapy in the management of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1349-1351.	0.6	0

#	ARTICLE	IF	CITATIONS
207	The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e98-e107.	2.0	25
208	Metastatic bone disease: Pathogenesis and therapeutic options. <i>Journal of Bone Oncology</i> , 2019, 15, 100205.	1.0	153
209	Navigating the treatment landscape in multiple myeloma: which combinations to use and when?. <i>Annals of Hematology</i> , 2019, 98, 1-18.	0.8	62
210	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	2.3	10
211	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1039-1044.	2.0	11
212	Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. <i>Haematologica</i> , 2019, 104, 1026-1035.	1.7	17
213	A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1692-1698.	0.5	2
214	Novel controlled drug release system engineered with inclusion complexes based on carboxylic graphene. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 175, 18-25.	2.5	10
215	Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA. <i>Expert Review of Hematology</i> , 2019, 12, 71-79.	1.0	2
216	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2019, 109, 79-90.	0.7	9
217	The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. <i>Leukemia</i> , 2019, 33, 546-549.	3.3	26
218	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e30-e37.	0.2	75
219	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	1.7	16
220	Management of induction failures in newly diagnosed transplant-eligible multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1-3.	0.6	1
221	Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 118-124.	0.1	2
222	Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 668-679.	0.6	5
223	Connect MM Registry as a national reference for United States multiple myeloma patients. <i>Cancer Medicine</i> , 2020, 9, 35-42.	1.3	14
224	Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis. <i>International Journal of Hematology</i> , 2020, 111, 103-111.	0.7	4

#	ARTICLE	IF	CITATIONS
225	Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. <i>International Journal of Hematology</i> , 2020, 111, 65-74.	0.7	11
226	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1640-1650.	2.0	28
227	Multiple Myeloma and Related Disorders. , 2020, , 1884-1910.e7.		4
228	Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. <i>Hematological Oncology</i> , 2020, 38, 229-243.	0.8	28
229	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 665-671.	2.0	21
230	Limited treatment options in refractory multiple myeloma: promising therapeutic developments. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 31-44.	1.1	5
231	The efficacy and safety of modified bortezomib+lenalidomide+dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2020, 104, 110-115.	1.1	7
232	Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020, 82, 101929.	3.4	42
233	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 798-804.	2.0	28
234	Quadruplets come of age for newly diagnosed multiple myeloma. <i>Lancet, The</i> , 2020, 395, 94-96.	6.3	2
235	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 784-792.	0.8	175
236	Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 137-145.	0.8	5
237	The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. <i>Blood Reviews</i> , 2020, 41, 100643.	2.8	26
238	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	0.8	56
239	The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study. <i>Hemato</i> , 2020, 1, 36-48.	0.2	3
240	Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e910-e925.	0.2	9
241	Multiple myeloma current treatment algorithms. <i>Blood Cancer Journal</i> , 2020, 10, 94.	2.8	178
242	Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020. <i>Cancers</i> , 2020, 12, 2885.	1.7	23

#	ARTICLE	IF	CITATIONS
243	Colon perforation in multiple myeloma patients – A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020, 9, 8895-8901.	1.3	3
244	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis. <i>Advances in Therapy</i> , 2020, 37, 4996-5009.	1.3	2
245	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	1.2	8
246	Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. <i>Cancer Medicine</i> , 2020, 9, 8923-8930.	1.3	4
247	Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 736-743.	0.2	5
248	Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. <i>Journal of Clinical Medicine</i> , 2020, 9, 3626.	1.0	4
249	The Road to a Cure: Emerging Treatments for Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3593.	1.7	0
250	Sequencing multiple myeloma therapies with and after antibody therapies. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 248-258.	0.9	10
251	Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody-based treatment?. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 259-263.	0.9	6
252	Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 3295-3301.	2.5	20
253	Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice: Deliberations and recommendations from an expert panel of hematologists. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1210-1216.	0.5	4
254	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	0.6	56
255	Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. <i>Cancer</i> , 2020, 126, 4332-4340.	2.0	18
256	Immunotherapeutic and Targeted Approaches in Multiple Myeloma. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 201-215.	2.7	14
257	Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients. <i>Cancers</i> , 2020, 12, 3106.	1.7	12
259	How I Manage Frontline Transplant-Ineligible Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 8956.	0.3	6
260	Use of daratumumab in high risk multiple myeloma: A meta-analysis. <i>EJHaem</i> , 2020, 1, 267-271.	0.4	15
261	Emerging immunotherapies in multiple myeloma. <i>BMJ</i> , 2020, 370, m3176.	3.0	62

#	ARTICLE	IF	CITATIONS
262	Emerging Insights on the Biological Impact of Extracellular Vesicle-Associated ncRNAs in Multiple Myeloma. <i>Non-coding RNA</i> , 2020, 6, 30.	1.3	7
263	Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma – Moving Toward a Personalized Approach. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S76-S80.	0.2	2
264	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 1317-1330.	5.1	155
265	Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice. <i>Journal of Personalized Medicine</i> , 2020, 10, 120.	1.1	13
266	<p>Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7891-7903.	0.9	32
267	Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. <i>Annals of Hematology</i> , 2020, 99, 2589-2598.	0.8	19
268	Daratumumab+lenalidomide+dexamethasone vs standard+of+care regimens: Efficacy in transplant+ineligible, untreated myeloma. <i>American Journal of Hematology</i> , 2020, 95, 1486-1494.	2.0	25
271	Super-Enhancer Associated Five-Gene Risk Score Model Predicts Overall Survival in Multiple Myeloma Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 596777.	1.8	12
272	Managing Multiple Myeloma in the Face of Drug-Induced Adverse Drug Reaction. <i>Journal of Pharmacy Practice</i> , 2020, , 089719002097776.	0.5	1
273	Recommendations on the management of multiple myeloma in 2020. <i>Acta Clinica Belgica</i> , 2020, , 1-17.	0.5	1
274	Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1616-1626.	0.4	11
275	Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data. <i>Frontiers in Pharmacology</i> , 2020, 11, 561601.	1.6	9
276	Emerging agents and regimens for multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 150.	6.9	55
277	Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 3554.	1.0	4
278	Real+world treatment patterns and outcomes in non+transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom. <i>European Journal of Haematology</i> , 2020, 105, 308-325.	1.1	11
279	Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). <i>Blood Cancer Journal</i> . 2020. 10. 53.	2.8	131
280	Multiple myeloma: Current and future management in the aging population. <i>Maturitas</i> , 2020, 138, 8-13.	1.0	7
281	The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. , 2020, 213, 107579.		62

#	ARTICLE	IF	CITATIONS
282	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020, 136, 936-945.	0.6	436
283	The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma. <i>Frontiers in Oncology</i> , 2020, 10, 676.	1.3	3
284	<p>Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide</p>. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 619-633.	1.3	10
285	Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1285-1292.	0.5	14
286	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2647-2657.	0.8	24
287	The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?. <i>British Journal of Haematology</i> , 2020, 191, 692-703.	1.2	23
288	Treatment disparities in minority groups with multiple myeloma at a safety-net hospital. <i>Leukemia and Lymphoma</i> , 2020, 61, 2507-2510.	0.6	4
289	Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd). <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092104.	1.1	2
290	Lenalidomide and pomalidomide potentially interfere with induction of myeloid-derived suppressor cells in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 784-795.	1.2	28
291	Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019. <i>European Journal of Haematology</i> , 2020, 105, 434-448.	1.1	2
292	The Struggle Is Real: Practice Patterns for the "Myelennial" Generation. <i>JCO Oncology Practice</i> , 2020, 16, 17-18.	1.4	0
293	A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2020, 13, 435-445.	1.0	5
294	Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 105, 56-65.	1.1	9
295	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020, 13, 421-433.	1.0	34
296	Immunotherapy in Multiple Myeloma. <i>Cells</i> , 2020, 9, 601.	1.8	27
297	Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. <i>Blood Cancer Journal</i> , 2020, 10, 33.	2.8	26
298	Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 548-567.	2.0	507
299	Proteomics-inspired precision medicine for treating and understanding multiple myeloma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 67-85.	0.4	7

#	ARTICLE	IF	CITATIONS
301	Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 60-70.	1.0	9
302	Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings. <i>JAMA Network Open</i> , 2020, 3, e203842.	2.8	29
303	Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date. <i>Seminars in Oncology</i> , 2020, 47, 155-164.	0.8	11
304	Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 13.	2.8	5
305	Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1323-1333.	0.6	18
306	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	3.3	54
307	The safety of current and emerging therapies for multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 269-279.	1.0	6
308	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	2.8	75
309	Treatment and disease-related complications in multiple myeloma: Implications for survivorship. <i>American Journal of Hematology</i> , 2020, 95, 672-690.	2.0	22
310	Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. <i>International Journal of Hematology</i> , 2020, 111, 512-518.	0.7	7
311	The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2020, 11, 369-379.	0.5	20
312	Early monoclonal protein decline pattern is an independent prognostic factor in patients with multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 581-589.	0.8	2
313	Non-transplant eligible multiple myeloma: deciphering optimal first line regimens. <i>Leukemia and Lymphoma</i> , 2020, 61, 504-506.	0.6	0
314	Current Treatment Strategies for Multiple Myeloma. <i>JCO Oncology Practice</i> , 2020, 16, 5-14.	1.4	28
315	The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies—back to the future!. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101150.	0.7	7
316	Second malignancies in multiple myeloma; emerging patterns and future directions. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101144.	0.7	27
317	Peripheral neuropathy in hematologic malignancies — Past, present and future. <i>Blood Reviews</i> , 2020, 43, 100653.	2.8	16
318	Proteasome Inhibitors for the Treatment of Multiple Myeloma. <i>Cancers</i> , 2020, 12, 265.	1.7	109

#	ARTICLE	IF	CITATIONS
319	GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLoS ONE, 2020, 15, e0228408.	1.1	2
320	Modern treatments and future directions for newly diagnosed multiple myeloma patients. Best Practice and Research in Clinical Haematology, 2020, 33, 101151.	0.7	6
321	Autologous haematopoietic stem-cell transplantation versus bortezomib+melphalan+prednisone, with or without bortezomib+lenalidomide+dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematology, the, 2020, 7, e456-e468.	2.2	244
322	A pharmacodynamic model of clinical synergy in multiple myeloma. EBioMedicine, 2020, 54, 102716.	2.7	20
323	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2020, 61, 1850-1859.	0.6	11
324	EHA evaluation of the ESMO Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open, 2020, 5, e000611.	2.0	10
325	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica, 2020, 105, 2879-2882.	1.7	20
326	Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond. Expert Review of Hematology, 2020, 13, 669-686.	1.0	8
328	The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. Annals of Hematology, 2020, 99, 1709-1725.	0.8	12
329	Newly Diagnosed Myeloma in 2020. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e144-e158.	1.8	9
330	Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review. Journal of Clinical Oncology, 2020, 38, 2558-2569.	0.8	110
331	Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. Blood Reviews, 2021, 46, 100732.	2.8	18
332	Advances & future prospects in newly diagnosed multiple myeloma patients. Advances in Cell and Gene Therapy, 2021, 4, .	0.6	1
333	Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). British Journal of Haematology, 2021, 192, 531-541.	1.2	9
334	Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect [®] MM Registry. British Journal of Haematology, 2021, 193, 93-100.	1.2	4
335	Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation, 2021, 56, 368-375.	1.3	8
336	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. British Journal of Haematology, 2021, 192, 853-868.	1.2	14
337	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia, 2021, 35, 809-822.	3.3	7

#	ARTICLE	IF	CITATIONS
338	Multiple Myelomaâ€™Effect of Induction Therapy on Transplant Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 80-90.e5.	0.2	10
339	Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study. <i>Advances in Therapy</i> , 2021, 38, 640-659.	1.3	7
340	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as firstâ€line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 330-337.	2.0	13
341	Myeloma clinical outcomes following the first wave of COVIDâ€™19: results from the Thames Valley Cancer Alliance (UK). <i>British Journal of Haematology</i> , 2021, 192, e136-e139.	1.2	2
342	A phase 1b study of onceâ€weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 226-233.	2.0	5
343	The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review. <i>Annals of Hematology</i> , 2021, 100, 405-419.	0.8	4
344	Serial comprehensive geriatric and quality of life assessments in adults ageâ€™50 years undergoing autologous hematopoietic cell transplantation. <i>Journal of Geriatric Oncology</i> , 2021, 12, 531-539.	0.5	6
345	Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents. <i>International Journal of Hematology</i> , 2021, 113, 207-213.	0.7	9
346	Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 125-135.	0.6	3
347	Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. <i>Blood Reviews</i> , 2021, 46, 100758.	2.8	8
348	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021, 35, 1722-1731.	3.3	35
349	Outcomes of lenalidomideâ€or bortezomibâ€based regimens in older patients with plasma cell myeloma. <i>American Journal of Hematology</i> , 2021, 96, 14-22.	2.0	4
350	Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. <i>Seminars in Cancer Biology</i> , 2021, 68, 105-122.	4.3	27
351	The Role of Targeted Therapy in Multiple Myeloma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2021, , 1-15.	0.1	0
352	Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Effectivity and Adverse Events. <i>Turkish Journal of Haematology</i> , 2021, 38, 41-48.	0.2	0
353	Practical management and assessment of primary plasma cell leukemia in the novel agent era. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100414.	0.7	1
354	Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. <i>Current Oncology</i> , 2021, 28, 640-660.	0.9	31
355	Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis. <i>Annals of Hematology</i> , 2021, 100, 563-573.	0.8	13

#	ARTICLE	IF	CITATIONS
356	Old and new generation immunomodulatory drugs in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 207-219.	0.2	4
357	DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 504.	1.7	14
358	Old and new generation proteasome inhibitors in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 193-206.	0.2	6
359	Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. <i>Frontiers in Oncology</i> , 2020, 10, 606368.	1.3	23
361	Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study. <i>Leukemia Research</i> , 2021, 101, 106498.	0.4	1
362	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib+â€‰dexa-methasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 20.	2.8	11
363	Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma. <i>Global Journal of Cancer Therapy</i> , 2021, , 010-015.	0.4	0
364	Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 575168.	1.3	8
365	Role of Stem Cell Transplantation in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 863.	1.7	17
366	Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. <i>Blood Advances</i> , 2021, 5, 725-736.	2.5	19
367	Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects. <i>Frontiers in Medicine</i> , 2021, 8, 612696.	1.2	13
368	Realâ€‰world outcomes with bortezomibâ€‰containing regimens and lenalidomide plus dexamethasone for the treatment of transplantâ€‰ineligible multiple myeloma: a multiâ€‰institutional report from the Canadian Myeloma Research Group database. <i>British Journal of Haematology</i> , 2021, 193, 532-541.	1.2	9
369	Retrospective Analysis of Presentation, Treatment, and Outcomes of Multiple Myeloma at a Large Public Referral Hospital in Eldoret, Kenya. <i>JCO Global Oncology</i> , 2021, 7, 391-399.	0.8	4
370	Expert review on softâ€‰tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
371	Management of acute kidney injury in symptomatic multiple myeloma. <i>Kidney International</i> , 2021, 99, 570-580.	2.6	31
372	The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma. <i>Anti-Cancer Drugs</i> , 2021, 32, 227-232.	0.7	6
373	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3616-3628.	0.6	48
374	Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China. <i>Medical Science Monitor</i> , 2021, 27, e930241.	0.5	6

#	ARTICLE	IF	CITATIONS
375	Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e213497.	2.8	7
376	How to Treat High-Risk Myeloma at Diagnosis and Relapse. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 291-309.	1.8	27
377	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
378	Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. <i>British Journal of Haematology</i> , 2021, 193, 245-268.	1.2	24
379	The initial management of multiple myeloma in the era of novel agents: 2021 and beyond. <i>British Journal of Haematology</i> , 2021, 193, 213-215.	1.2	0
380	Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 1002.	1.0	0
381	Immunomodulators in newly diagnosed multiple myeloma: current and future concepts. <i>Expert Review of Hematology</i> , 2021, 14, 365-376.	1.0	4
382	The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1235.	1.7	16
383	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 309-322.	0.6	316
384	Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1050-1065.	2.5	11
385	Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles. <i>Frontiers in Oncology</i> , 2021, 11, 652063.	1.3	16
386	Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches. <i>Journal of Clinical Medicine</i> , 2021, 10, 1841.	1.0	30
387	Genetic Predictors of Mortality in Patients with Multiple Myeloma. <i>The Application of Clinical Genetics</i> , 2021, Volume 14, 241-254.	1.4	6
388	Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. <i>American Journal of Hematology</i> , 2021, 96, 690-697.	2.0	13
389	Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1119-1128.	0.8	23
390	Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 148-161.	1.2	4
391	Current approaches to management of high-risk multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 854-871.	2.0	19
392	Current and Novel Alkylators in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2465.	1.7	12

#	ARTICLE	IF	CITATIONS
393	From Bench to Bedside. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 213-221.	1.0	1
394	Co-evolution of tumor and immune cells during progression of multiple myeloma. <i>Nature Communications</i> , 2021, 12, 2559.	5.8	68
395	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	2.8	14
396	Maintenance Strategies for Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 231-238.	1.0	0
397	Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1059-1066.	0.6	0
398	Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper. <i>Journal of Geriatric Oncology</i> , 2021, 12, 499-507.	0.5	7
399	Effect of age and frailty on the efficacy and tolerability of onceâ€weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	2.0	16
400	From VAD to VRD. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 190-195.	1.0	1
401	Induction Therapy Strategies in the Transplant-Ineligible Population. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 196-200.	1.0	1
402	Monoclonal Antibodies in Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 222-230.	1.0	2
403	Advances in Management for Older Adults With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 2102-2114.	0.8	24
404	Strategies to Overcome High-Risk Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 201-204.	1.0	0
405	Dose intensity and treatment duration of bortezomib in transplantâ€ineligible newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 246-254.	1.1	2
406	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 701-710.	0.2	4
407	Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment. <i>Leukemia Research</i> , 2021, 105, 106566.	0.4	19
408	Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China. <i>Frontiers in Oncology</i> , 2021, 11, 665217.	1.3	1
409	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	0.6	40
410	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.	3.4	63

#	ARTICLE	IF	CITATIONS
411	Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 682658.	1.3	2
412	Management of patients with difficult-to-treat multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2089-2105.	1.1	1
413	Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 975-984.	1.2	12
414	Initial Therapeutic Approaches to Patients with Multiple Myeloma. <i>Advances in Therapy</i> , 2021, 38, 3694-3711.	1.3	5
415	Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2021, 62, 2492-2501.	0.6	6
416	Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 191-203.	1.2	3
417	Sequencing of myeloma therapy: Finding the right path among many standards. <i>Hematological Oncology</i> , 2021, 39, 68-72.	0.8	6
418	Characterize, Optimize, and Harmonize: Caring for Older Adults With Hematologic Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e266-e274.	1.8	3
419	Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. <i>BMC Cancer</i> , 2021, 21, 730.	1.1	23
420	Updates in the management of relapsed/refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1477-1490.	0.5	2
421	Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. <i>European Journal of Haematology</i> , 2021, 107, 466-474.	1.1	1
422	Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	0
423	Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions. <i>JCO Oncology Practice</i> , 2021, 17, 415-418.	1.4	2
424	Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 703233.	1.3	6
425	Developing next generation immunomodulatory drugs and their combinations in multiple myeloma. <i>Oncotarget</i> , 2021, 12, 1555-1563.	0.8	28
426	Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 2745-2754.	0.8	2
427	Collet-Sicard syndrome due to concurrent extramedullary intracranial plasmacytoma and jugular venous sinus thrombosis in multiple myeloma. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04457.	0.2	3
428	Carfilzomib-Based 3-Drug Regimens for Newly Diagnosed Multiple Myeloma—All That Glitters Is Not Gold. <i>JAMA Oncology</i> , 2021, 7, 967.	3.4	0

#	ARTICLE	IF	CITATIONS
429	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	0.6	2
430	Knowing the unknowns in high risk multiple myeloma. <i>Blood Reviews</i> , 2022, 51, 100887.	2.8	6
431	Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. <i>International Journal of Cancer</i> , 2021, 149, 1980-1996.	2.3	25
432	Light Chain- Predominant Multiple Myeloma Subgroup: Impaired Renal Function Correlates with Decreased Survival. <i>Laboratory Medicine</i> , 2022, 53, 145-148.	0.8	7
433	Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review. <i>Current Cancer Therapy Reviews</i> , 2021, 17, 234-243.	0.2	0
434	Targeting BCMA in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 367-383.	1.2	6
435	Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2758-2767.	0.8	25
436	Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1005-1009.	0.5	4
437	A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). <i>Blood Cancer Journal</i> , 2021, 11, 150.	2.8	2
438	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	0.8	25
439	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. <i>Blood Reviews</i> , 2021, 49, 100808.	2.8	27
440	Recent therapeutic approaches in myeloma. , 2022, , 1019-1029.		0
441	Epidemiology, Staging, and Management of Multiple Myeloma. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 3.	1.3	79
442	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100444.	0.7	5
443	The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110196.	1.1	8
444	New regimens and directions in the management of newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 367-378.	2.0	8
446	Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1243, 147-162.	0.8	8
447	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1394-1401.	2.0	8

#	ARTICLE	IF	CITATIONS
448	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 2021, 5, e528.	1.2	45
449	Best of 2017 in Multiple Myeloma. , 2018, 15, .		1
450	Roundtable: How I treat a newly diagnosed patient with high-risk myeloma. Hematology American Society of Hematology Education Program, 2019, 2019, 120-124.	0.9	5
451	Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. JCO Oncology Practice, 2020, 16, 56-66.	1.4	31
452	Myeloma in Elderly Patients: When Less Is More and More Is More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 575-585.	1.8	20
453	How I treat elderly patients with plasma cell dyscrasias. Aging, 2018, 10, 4248-4268.	1.4	9
454	Emerging drugs and combinations to treat multiple myeloma. Oncotarget, 2017, 8, 60656-60672.	0.8	39
455	Prognostic significance of the red blood cell distribution width that maintain at high level following completion of first line therapy in mutiple myeloma patients. Oncotarget, 2018, 9, 10118-10127.	0.8	6
456	VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization. Acta Haematologica Polonica, 2020, 51, 42-46.	0.1	1
457	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 3120.	1.0	35
458	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. Oncology Letters, 2019, 18, 5811-5820.	0.8	4
459	Induction therapy in newly diagnosed multiple myeloma: Current research scenario and questions for the future. Cancer Research Statistics and Treatment, 2019, 2, 76.	0.1	12
460	Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Medical Weekly, 2019, 149, w20031.	0.8	4
461	Frontline therapy for newly diagnosed patients with multiple myeloma. Blood Research, 2020, 55, S37-S42.	0.5	12
462	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1685-1717.	2.3	138
463	Defining and Managing High-Risk Multiple Myeloma: Current Concepts. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1730-1737.	2.3	21
464	Clarifying the molecular mechanism of tomentosin-induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis. International Journal of Molecular Medicine, 2021, 48, .	1.8	2
465	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	3.3	43

#	ARTICLE	IF	CITATIONS
466	Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients. Expert Review of Hematology, 2021, , 1-14.	1.0	1
467	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leukemia and Lymphoma, 2022, 63, 710-721.	0.6	8
468	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 1582-1596.	5.1	141
469	Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma. Archives of Pathology and Laboratory Medicine, 2022, 146, 862-871.	1.2	7
470	Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study. Cancer Medicine, 2021, , .	1.3	7
471	An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission. Clinical Cancer Research, 2021, 27, 6696-6708.	3.2	8
472	Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium. Diagnostics, 2021, 11, 1872.	1.3	3
473	A comprehensive approach to therapy of haematological malignancies in older patients. Lancet Haematology,the, 2021, 8, e840-e852.	2.2	17
474	Is Upfront Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma the Standard?. , 2017, 14, .		1
477	Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma. Oncogematologiya, 2019, 14, 14-19.	0.1	2
479	Next-generation immunomodulatory drugs in multiple myeloma. Postepy Higieny I Medycyny Doswiadczalnej, 2019, 73, 791-802.	0.1	0
480	Onkologika. , 2020, , 671-732.		2
481	Comparative Performance of Whole-Body MRI and FDG PET/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2022, 218, 602-613.	1.0	14
482	Multiple Myeloma in Older Adults. , 2020, , 549-565.		0
484	Bonanza of New Treatment Regimens for Multiple Myeloma: What Is Right for My Patient?. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1773-1776.	2.3	0
485	Light Chain-Predominant Multiple Myeloma Subgroup; Impaired Renal Function Correlates with Decreased Survival in this Subgroup. SSRN Electronic Journal, 0, , .	0.4	0
486	State of the Art for Metastatic Histologies. , 2020, , 211-233.		0
487	Identification of glutathione S-transferase ĩ1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling. Oncology Letters, 2020, 19, 2153-2162.	0.8	1

#	ARTICLE	IF	CITATIONS
488	Treatment of multiple myeloma in 2021. <i>Klinicka Farmakologie A Farmacie</i> , 2021, 35, 70-77.	0.1	2
489	Identification of patients at high risk of secondary extramedullary multiple myeloma development. <i>British Journal of Haematology</i> , 2021, , .	1.2	8
490	How I treat high-risk multiple myeloma. <i>Blood</i> , 2022, 139, 2889-2903.	0.6	17
491	Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma. <i>South Asian Journal of Cancer</i> , 2020, 09, 233-235.	0.2	0
492	Consenso del Grupo Latinoamericano de estudio de Mieloma Múltiple (MM) GELAMM para el manejo del MM en estado de Pandemia SARS CoV-2 / COVID 19. <i>Revista Colombiana De Cancerología</i> , 0, 24, .	0.0	2
493	Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 559-568.	0.3	8
496	<i>Multiples Myelom.</i> , 2022, , 204-211.		0
497	Nonselective proteasome inhibitors in multiple myeloma and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 335-347.	0.9	4
498	Preceding bortezomib administration for a certain period reduces the risk of lenalidomide-induced skin rash. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, , .	0.7	0
499	Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1347-1350.	2.3	0
500	Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia. <i>Seminars in Oncology</i> , 2021, , .	0.8	0
501	Genome Instability in Multiple Myeloma: Facts and Factors. <i>Cancers</i> , 2021, 13, 5949.	1.7	17
502	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 83.e1-83.e9.	0.6	9
503	SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 279-286.	0.2	1
504	Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma. <i>Future Oncology</i> , 2022, 18, 553-564.	1.1	4
505	Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1691-1702.	0.5	1
506	<i>Onkologika.</i> , 2021, , 579-638.		0
507	Treatment for multiple myeloma in hospital at home: clinical characteristics and patient care pathways. <i>Home Health Care Services Quarterly</i> , 2022, 41, 165-181.	0.3	1

#	ARTICLE	IF	CITATIONS
508	Management of acute kidney injury in frail patients with biopsy-proven cast nephropathy: a combined approach with chemotherapy plus Supra-hemodiafiltration with post-adsorption endogenous reinfusion. <i>Journal of Nephrology</i> , 2022, 35, 1243-1249.	0.9	2
509	HÃmatologie: M. Hodgkin und Myelom. , 0, , .		0
510	Current Treatment Approaches to Newly Diagnosed Multiple Myeloma. <i>Oncology Research and Treatment</i> , 2021, 44, 690-699.	0.8	11
511	Pretransplant Determinants of Outcome in Patients with Myeloma Undergoing Autologous Transplantation in Lower Resource Settings. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 101-110.	3.0	0
512	Management of Multiple Myeloma in Older Patients. <i>European Medical Journal Hematology</i> , 0, , 69-81.	0.0	1
513	Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics. <i>Frontiers in Oncology</i> , 2021, 11, 800309.	1.3	1
514	Daratumumab: A review of current indications and future directions. <i>Seminars in Oncology</i> , 2022, 49, 48-59.	0.8	4
515	The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. <i>Biomarker Research</i> , 2022, 10, 1.	2.8	22
516	Harnessing natural killer cells for the treatment of multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 69-85.	0.8	12
517	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 19-26.	0.8	5
518	Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. <i>Leukemia</i> , 2022, 36, 613-624.	3.3	11
519	Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, 562-573.	2.0	3
520	ÃÃNH GIÃ•HIÃ»†U QUÃ¡c Cá» A PHÃC ÃÁ»' CÃ“ BORTEZOMIB TRONG ÃÁ»EU TRÃÁ»Š BÃ-Ã»ŠC ÃÁº U ÃA U Tá» Y XÃE/ENG Táº BÃ†NH 2022, 510, .	0.0	0
521	Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. <i>Advances in Therapy</i> , 2022, 39, 1976-1992.	1.3	10
522	Belantamab mafodotin for relapsed or refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210862.	0.5	0
523	Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. <i>Seminars in Cancer Biology</i> , 2022, 86, 607-623.	4.3	10
524	Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma. <i>Frontiers in Oncology</i> , 2022, 12, 861709.	1.3	3
525	Current approaches to management of newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	18

#	ARTICLE	IF	CITATIONS
526	Patients with multiple myeloma or monoclonal gammopathy of undetermined significanceâ€”diagnosis, treatment, and follow-up. <i>Deutsches A&#x0308;rzteblatt International</i> , 2022, , .	0.6	2
527	Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have highâ€”risk cytogenetics: A metaâ€”analysis of randomized controlled trials. <i>Cancer</i> , 2022, , .	2.0	5
528	Restricted survival benefit with rightâ€”censored data. <i>Biometrical Journal</i> , 2021, , .	0.6	1
529	Ikaros Proteins in Tumor: Current Perspectives and New Developments. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 788440.	1.6	5
530	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	2.8	5
531	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. <i>Blood Cancer Journal</i> , 2022, 12, 63.	2.8	5
539	Drug Targeting and Conventional Treatment of Multiple Myeloma: Analysis of Target Specific Nanotherapies in Disease Models. <i>Current Drug Therapy</i> , 2022, 17, .	0.2	0
540	Update on primary plasma cell leukemia. <i>Blood Research</i> , 2022, 57, S62-S66.	0.5	7
541	Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	12
542	Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience. <i>Cancers</i> , 2022, 14, 2277.	1.7	8
543	Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. <i>Leukemia and Lymphoma</i> , 2022, 63, 2413-2421.	0.6	1
544	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	1.3	7
545	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> ,the, 2022, 9, e403-e414.	2.2	23
546	Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma. <i>Lancet Haematology</i> ,the, 2022, , .	2.2	0
547	Multiple myeloma with high-risk cytogenetics and its treatment approach. <i>International Journal of Hematology</i> , 2022, 115, 762-777.	0.7	30
548	Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2022, 97, 1086-1107.	2.0	208
550	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 264.e1-264.e9.	0.6	0
551	Pathogenesis and treatment of multiple myeloma. <i>MedComm</i> , 2022, 3, .	3.1	8

#	ARTICLE	IF	CITATIONS
552	Efficacy and safety of modified BLD therapy for Japanese patients with transplant-ineligible multiple myeloma. <i>International Journal of Hematology</i> , 2022, 116, 563-569.	0.7	1
553	High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 572-580.	0.6	5
554	Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. <i>Hematological Oncology</i> , 2022, 40, 987-998.	0.8	5
555	Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e1000-e1008.	0.2	1
556	Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
557	Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. <i>British Journal of Haematology</i> , 2022, 199, 190-204.	1.2	9
558	<i>Myeloma and Leukemia</i> . , 2023, , 503-528.		0
560	Minimal Residual Disease in Multiple Myeloma—Current Approaches and Future Clinical Implications. <i>Hemato</i> , 2022, 3, 454-465.	0.2	1
561	Treatment horizon in multiple myeloma. <i>European Journal of Haematology</i> , 2022, 109, 425-440.	1.1	6
562	A Focus on Relapsed Multiple Myeloma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 15-21.	0.2	0
563	Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. <i>BMC Cancer</i> , 2022, 22, .	1.1	10
564	EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, S24-S26.	0.2	0
565	Home is best. Self-administration of subcutaneous Bortezomib at home in patients with multiple myeloma - A mixed method study. <i>European Journal of Oncology Nursing</i> , 2022, 60, 102199.	0.9	2
566	Data-adaptive efficient estimation strategies for biomarker studies embedded in randomized trials. <i>Annals of Applied Statistics</i> , 2022, 16, .	0.5	0
567	Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia. <i>Current Oncology</i> , 2022, 29, 6236-6244.	0.9	2
568	Steps towards a Multiple Myeloma Cure?. <i>Journal of Personalized Medicine</i> , 2022, 12, 1451.	1.1	3
569	CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 4492.	1.7	12
570	Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant. <i>Cancer Medicine</i> , 2023, 12, 3145-3159.	1.3	1

#	ARTICLE	IF	CITATIONS
571	Multiple Myeloma in Patients over 80: A Real World Retrospective Study of First Line Conservative Approach with Bortezomib Dexamethasone Doublet Therapy and Mini-Review of Literature. <i>Cancers</i> , 2022, 14, 4741.	1.7	1
572	Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	1
574	Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30715.	0.4	0
575	Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations. <i>American Journal of Medicine</i> , 2023, 136, 33-41.	0.6	10
576	An update on the safety of ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 0, , 1-18.	1.0	0
577	Bispecific antibodies in multiple myeloma treatment: A journey in progress. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	17
578	Plasma cell neoplasms, multiple myeloma, solitary plasmacytoma a plasma cell leukemia. Clinical symptoms, diagnostic criteria and therapy. <i>Onkologie (Czech Republic)</i> , 2022, 16, 7-32.	0.0	0
580	Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 104-111.	0.2	0
581	Frontâ€line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a realâ€world setting: A multicenter retrospective study in China. <i>Cancer Medicine</i> , 0, , .	1.3	0
582	Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. <i>Lancet Haematology</i> , the, 2022, 9, e810-e821.	2.2	44
583	Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation. <i>World Journal of Clinical Cases</i> , 0, 10, 11712-11725.	0.3	0
584	Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM). <i>Leukemia Research</i> , 2022, 123, 106966.	0.4	0
586	Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients. <i>Future Oncology</i> , 2022, 18, 3983-3991.	1.1	2
588	Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. <i>ESMO Open</i> , 2022, 7, 100605.	2.0	0
589	PECULIARITIES OF MYOCARDIAL BIOELECTRIC ACTIVITY IN PATIENTS WITH PROGRESSIVE MYLTIPLE MYELOMA RECEIVING BORTEZOMIB-CONTAINING CHEMOTHERAPY SCHEMES. , 2022, 22, 80-84.	0.1	1
590	Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test. <i>AboutOpen</i> , 0, 9, 105-111.	0.2	0
592	Clinical, economical and ethical aspects assessing therapy outcomes in patients with multiple myelomas of high cytogenetic risk. , 2022, , .		0
593	Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 6216.	1.7	6

#	ARTICLE	IF	CITATIONS
594	The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma. <i>Advances in Therapy</i> , 2023, 40, 705-717.	1.3	1
595	Newly diagnosed multiple myeloma: making sense of the menu. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 539-550.	0.9	1
596	The emerging therapeutic landscape of relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2023, 102, 1-11.	0.8	12
597	Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, .	0.6	1
598	How I treat multiple myeloma in geriatric patients. <i>Blood</i> , 2024, 143, 224-232.	0.6	5
599	Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies. , 0, , .		0
600	The nephrotoxicity of bortezomib: did we miss a complication after 20 years of use and multiple landmark trials?. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.4	0
601	Spinal lesions in multiple myeloma: Primary bone tumors with distinct prognostic factors. <i>Surgical Oncology</i> , 2023, 48, 101927.	0.8	1
602	HÄmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
603	First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 340-354.	0.2	0
604	Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies. <i>JACC: CardioOncology</i> , 2023, 5, 1-21.	1.7	7
606	Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	7
607	Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. <i>Pharmaceuticals</i> , 2023, 16, 415.	1.7	7
608	Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study. <i>Oncologist</i> , 2023, 28, 462-e303.	1.9	1
609	Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	5
610	30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma. <i>Cancers</i> , 2023, 15, 1929.	1.7	4
611	Long-Term Outcomes of Autologous Hematopoietic Stem Cell Transplant (HSCT) for Multiple Myeloma: While New Horizons Emerge, It Is Still Only a Silver Lining for Resource-Constrained Settings. <i>Cureus</i> , 2023, , .	0.2	0
612	Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, , .	0.2	0

#	ARTICLE	IF	CITATIONS
613	Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. <i>Anti-Cancer Drugs</i> , 0, Publish Ahead of Print, .	0.7	0
646	Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 885-895.	12.5	2
677	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0